Filter: All News Events

Neovii Pharmaceuticals AG announces new CEO


Neovii completes marketing authorisation withdrawal of Removab® in the European Union


Long-term outcomes after standard graft-versus-host disease (GvHD) prophylaxis in hemopoietic cell transplantation from matched unrelated donors strongly support the use of Grafalon® (anti-human-T-lymphocyte immunoglobulin) as standard therapy


Neovii Pharmaceuticals AG licenses worldwide (excluding U.S. & Japan) developmental and commercialization rights for ARCALYST® (rilonacept) from Regeneron for the treatment of periodic fever syndromes


European study in patients with acute leukemia shows the inclusion of Grafalon® (anti T-lymphocyte immunoglobulin) in a conditioning regimen before stem cell transplantation from HLA-identical siblings results in a significantly lower incidence of chronic GvHD.